Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice

Vaccine

Volumn 29, Issue 46, 2011, Pages 8330-8337

  Harada, Yuichi ^a   Ninomiya Mori, Ai ^b   Takahashi, Yoshimasa ^a   Shirakura, Masayuki ^a   Kishida, Noriko ^a   Kageyama, Tsutomu ^a   Tada, Yoshikazu ^c   Tashiro, Masato ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KOBE INSTITUTE OF HEALTH   (Japan)

^c The Research Foundation for Microbial Diseases of Osaka University   (Japan)

Author keywords

Adjuvanted H5N1 whole virion pre pandemic influenza vaccine; Cross neutralizing antibodies; Cross protective immunity; H5N1 avian influenza

Indexed keywords

ALUMINUM HYDROXIDE; AVIAN INFLUENZA VACCINE; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; AVIAN INFLUENZA; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL RATE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS PROTECTION; CROSS REACTIONS; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 80053937526     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.091     Document Type: Article

References (35)

1. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351(February (9101)):472-477.
2. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(January (5349)):393-396.
3. World Health Organization Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO 2011, cited, Available from:. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_08_02/en/index.html.
4. Normile D. Avian influenza human transmission but no pandemic in Indonesia. Science 2006, 312(June (5782)):1855.
5. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004, 350(March (12)):1179-1188.
6. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005, 352(January (4)):333-340.
7. Ministry of Agriculture FaFoJ; 2011, cited; Available from: http://www.maff.go.jp/j/syouan/douei/tori/pdf/110405_ai_japan_map.pdf.
8. Ministry of Health LaW; 2004, cited; Available from: http://www.mhlw.go.jp/topics/bukyoku/kenkou/tori/041222/1.html.
9. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23(April (22)):2943-2952.
10. Dong J., Matsuoka Y., Maines T.R., Swayne D.E., O'Neill E., Davis C.T., et al. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respi Viruses 2009, 3(November (6)):287-295.
11. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363(April (9415)):1099-1103.
12. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(March (13)):1343-1351.
13. Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25(May (18)):3554-3560.
14. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27(August (37)):5091-5095.
15. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(September (9540)):991-997.
16. Naim J.O., van Oss C.J., Wu W., Giese R.F., Nickerson P.A. Mechanisms of adjuvancy: I-metal oxides as adjuvants. Vaccine 1997, 15(August (11)):1183-1193.
17. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(March (5)):667-675.
18. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9(August (8)):1057-1071.
19. Europian Medicines Agency. Aflunov, cited; Available from: http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002094/human_med_001396.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d125.
20. Europian Medicines Agency. Prepandemic influenza vaccine (H5N1) Novartis Vaccines and Diagnostic, cited; Available from: http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002269/human_med_001397.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d125.
21. Europian Medicines Agency. Prepandrix, cited; Available from: http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000822/human_med_000986.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d125.
22. Europian Medicines Agency. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, cited; Available from: http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/001206/human_med_001214.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d125.
23. World Health Organization Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines 2005, cited; Available from:. http://www.who.int/csr/disease/avian_influenza/guidelines/recommendationvaccine.pdf.
24. World Health Organization Antigenic and genetic characteristics of influenza A (H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines 2011, cited; Available from:. http://www.who.int/csr/disease/avian_influenza/guidelines/2011_02_h5_h9_vaccinevirusupdate.pdf.
25. Takahashi Y., Hasegawa H., Hara Y., Ato M., Ninomiya A., Takagi H., et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009, 199(June (11)):1629-1637.
26. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999, 163(December (12)):6448-6454.
27. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996, 26(September (9)):2062-2066.
28. Fazekas G., Rosenwirth B., Dukor P., Gergely J., Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol 1994, 24(December (12)):3063-3067.
29. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995, 69(April (4)):2075-2081.
30. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol 1980, 39(February (2)):435-441.
31. Reiss C.S., Schulman J.L. Cellular immune responses of mice to influenza virus vaccines. J Immunol 1980, 125(November (5)):2182-2188.
32. Wijburg O.L., van den Dobbelsteen G.P., Vadolas J., Sanders A., Strugnell R.A., van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur J Immunol 1998, 28(February (2)):479-487.
33. Lu X., Edwards L.E., Desheva J.A., Nguyen D.C., Rekstin A., Stephenson I., et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006, 24(November (44-46)):6588-6593.
34. World Health Organization Weekly epidemiological record 2011, cited; Available from:. http://www.who.int/wer/2011/wer8617.pdf.
35. Ministry of Health LaW. Annual health, labour and welfare report 2007-2008; 2008, cited; Available from: http://www.mhlw.go.jp/english/wp/wp-hw2//part2//p2c1s7a.pdf.